Drug Trial Radar · NCT03433898
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Feb 23, 2018
Primary completion
Jul 20, 2023
Study completion Jul 20, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 15, 2018
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of the BI 754091 monotherapy dose-finding part (Part I) of the trial are to investigate the following items in advanced solid tumours: * Safety, tolerability, and pharmacokinetics (PK) of BI 754091 as monotherapy. * Maximum tolerated dose (MTD) and/or recommended dose (RD) of BI 754091 monotherapy. The main objectives of the Combination dose-finding part (Part II) of the trial are to investigate the following items in advanced solid tumours: * Safety, tolerability, and PK of the combination treatment of BI 754091 and BI 754111. * MTD and/or RD of the combination treatment of BI 754091 and BI 754111. The main objectives of the expansion part (Part III) of the trial are: * To further investigate the safety, tolerability, and PK of the RD of BI 754091 and BI 754111 combination in patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular cancer or non-small cell lung cancer (NSCLC) * To explore the efficacy of the RD of the combination of BI 754091 and BI 754111 in patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular cancer or NSCLC
Conditions
- Neoplasms
Interventions
EzabenlimabDrug
Solution for infusion
BI 754111Drug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: Maximum Tolerated Dose (MTD) of EzabenlimabTime frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
- Part I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
- Part II: MTD of the Ezabenlimab Plus BI 754111 Combination TherapyTime frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
- Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
- Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the InvestigatorTime frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 49 months.
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Kanagawa Cancer Center
Kanagawa, Yokohama, Japan
Saitama Cancer Center
Saitama, Kitaadachi-gun, Japan
Shizuoka Cancer Center
Shizuoka, Sunto-gun, Japan
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, Japan
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
NCKUH
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital(Linkou)
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.